Human Microbiome Market Worth USD 1,731 Million by 2027 - Leading Companies are Enterome Bioscience (France), Seres Therapeutics (US), and 4D Pharma (UK)

According to the new market research report "Human Microbiome Market by Product (Prebiotic, Probiotic, Food, Medical Food, Drug), Application (Therapeutic), Disease (Infectious, Metabolic/Endocrine, Cancer, Blood, Neurological), Research Technology (Proteomics, Metabolomics) - Global Forecast to 2027", published by MarketsandMarkets™,

The Human Microbiome Market is expected to grow from USD 942 million in 2024 to USD 1,731 million by 2027, at a CAGR of 22.5 % during the forecast period.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904#utm_source=Openpr&utm_medium=paidpr

Microbiomes are responsible for a wide variety of metabolic and developmental processes—from food digestion to vitamin synthesis and even brain function. They also play a major role in human conditions, such as obesity and inflammatory bowel disease.

The probiotics segment to account for the largest share of the global Human Microbiome Market in 2022

Based on product, the Human Microbiome Market is segmented into probiotics, prebiotics, foods, medical foods, diagnostic tests, and drugs. The probiotics segment is expected to account for the largest share of the Human Microbiome Market in 2022. The increasing awareness of probiotics for the prevention and treatment of various lifestyle & chronic diseases and health benefits of probiotics over conventional medicines, such as antibiotics are some of the major factors driving the growth of this segment.

Browse in-depth TOC on "Human Microbiome Market"
82 – Tables
22 – Figures
128 – Pages
Get 10% Customization Research Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=37621904#utm_source=Openpr&utm_medium=paidpr

The therapeutics segment to account for the largest share of the market in 2022

Based on application, the Human Microbiome Market is segmented into therapeutics and diagnostics. The therapeutics segment is expected to dominate the market in 2022. This is due to the need for the development of reliable, precise, and quicker treatment of chronic lifestyle diseases and various other disorders.

The infectious diseases segment to account for the largest share of the market in 2022

Based on disease, the Human Microbiome Market is segmented into five categories—infectious diseases, endocrine & metabolic disorders, inflammatory diseases, cancer, and other diseases. The infectious disease segment is expected to dominate the market in 2022. This is due to the increasing research in microbiome-based products and their use in treating infectious diseases. Many smaller companies are investing in research, and their major focus is on developing products targeting microbiome modulators for infectious diseases.

Europe to account for the largest share of the Human Microbiome Market in 2022

On the basis of region, the global Human Microbiome Market is segmented into four major geographies— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). Europe is expected to account for the largest share of the global Human Microbiome Market in 2022. The large share of this regional segment is mainly due to the high research activity in this region.

Request for Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904#utm_source=Openpr&utm_medium=paidpr

Key Players

Enterome Bioscience (Europe), Seres Therapeutics (US), Pharma PLC (UK), UBiome (US), E.I. du Pont de Nemours and Company (DuPont) (US), Synlogic (US), Second Genome (US), Vedanta Biosciences (US), Ferring Pharmaceuticals (Switzerland), Evelo Biosciences (US), ViThera Pharmaceuticals (US), BiomX (Israel), and LNC Therapeutics (France)

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

About MarketsandMarkets
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth emerging opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's™ flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.